• Skip to content
  • Skip to navigation

Grant Thornton Australia

Grant Thornton uses cookies to monitor the performance of this website and improve user experience.

If you are happy to accept cookies from this site, please check the box.

To find out more about cookies, what they are and how we use them, please see our privacy notice, which also provides information on how to delete cookies from your hard drive.

How to be COVIDSafe when visiting Grant Thornton offices. Find out how

Global site
  • Global site
  • Algeria
  • Botswana
  • Cameroon
  • Egypt
  • Ethiopia
  • Gabon
  • Guinea
  • Kenya
  • Libya
  • Malawi
  • Mauritius
  • Morocco
  • Nigeria
  • Namibia
  • Senegal
  • South Africa
  • Togo
  • Tunisia
  • Uganda
  • Zambia
  • Zimbabwe
  • Anguilla
  • Antigua
  • Argentina
  • Aruba, Bonaire, Curacao and St. Maarten
  • Bahamas
  • Barbados
  • Bolivia
  • Brazil
  • British Virgin Islands
  • Canada LLP
  • Canada RCGT
  • Cayman Islands
  • Chile
  • Colombia
  • Costa Rica
  • Dominica
  • Ecuador
  • El Salvador
  • Grenada
  • Guatemala
  • Honduras
  • Mexico
  • Montserrat
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • Puerto Rico
  • St Kitts
  • St Lucia
  • St Vincent and the Grenadines
  • Trinidad & Tobago
  • United States
  • Uruguay
  • Venezuela
  • Turks & Caicos
  • Afghanistan
  • Australia
  • Bangladesh
  • Cambodia
  • China
  • Hong Kong
  • India
  • Indonesia
  • Japan
  • Korea
  • Malaysia
  • Mongolia
  • Myanmar
  • New Zealand
  • Pakistan
  • Philippines
  • Singapore
  • Taiwan
  • Thailand
  • Vietnam
  • Albania
  • Armenia
  • Austria
  • Azerbaijan
  • Belarus
  • Belgium
  • Bosnia and Herzegovina
  • Bulgaria
  • Channel Islands
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Georgia
  • Germany
  • Gibraltar
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Isle of Man
  • Israel
  • Italy - Bernoni
  • Italy - Ria
  • Kazakhstan
  • Kosovo
  • Kyrgyzstan
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malta
  • Moldova
  • Monaco
  • Netherlands
  • Northern Ireland
  • Norway
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Tajikistan
  • Turkey
  • Ukraine
  • UK
  • Uzbekistan
  • Bahrain
  • Egypt
  • Jordan
  • Kuwait
  • Oman
  • Qatar
  • Saudi Arabia
  • United Arab Emirates
  • Yemen
  • Lebanon
Grant Thorton Logo

Grant Thornton Logo Grant Thornton Logo

Contact us
  • Insights
  • Services
  • Industries
  • Meet our people
  • Careers
  • News centre
  • Locations
  • About us
  • Audit
  • Tax
  • Private Advisory
  • Financial Advisory
  • Grant Thornton Consulting
  • Asia
Audit Home
  • Audit methodology
  • Audit technology
  • Financial reporting advisory
Tax Home
  • Corporate tax
  • Employee equity reward schemes
  • Fringe benefits tax
  • Global mobility services
  • GST & indirect tax
  • International tax
  • Payroll assurance
  • Research & development
  • Tax compliance
  • Tax governance & risk management
  • Tax in mergers & acquisitions
  • Tax lawyers
  • Transfer pricing
Private Advisory Home
  • Family Business Consulting
  • Family office services
  • Private wealth
  • Superannuation
Financial Advisory Home
  • Corporate finance
  • Debt advisory
  • Forensic consulting
  • Payments advisory
  • Restructuring advisory
Grant Thornton Consulting Home
  • Business risk
  • Human capital
  • Performance improvement
  • Strategy & growth
  • Technology consulting
  • GNC Group Consulting
Asia Home
  • China practice
  • India practice
  • Japan practice
  • Agribusiness, food & beverage
  • Automotive dealers
  • Education
  • Energy & resources
  • Financial services
  • Health & aged care
  • Life sciences
  • Manufacturing
  • Not for Profit
  • Professional services
  • Public sector
  • Real estate & construction
  • Retail & consumer products
  • Technology & media
Agribusiness, food & beverage Home
Bite Size Dealtracker Food, Beverage & Agribusiness industry insights
Key insights for the Australian Food, Beverage & Agribusiness industry.
Financial services Home
  • Banking
  • Fintech
  • Private Health Insurance
  • Superannuation
  • Asset management
  • BEAR FAQs
  • Open banking
Royal Commission wrap up Top 10 things for Financial Services providers
Eleven months on from the first round of hearings for the Royal Commission into Misconduct in the Banking, Superannuation and Financial Services Industry, Commissioner Hayne’s final report has been released.
Health & aged care Home
Aged Care Royal Commission Perspectives on the Future of Ageing
Transitions in ageing are not consistent and systematic as they are described by our ageing systems. Sometimes they are incremental, sometimes accidental, sometimes monumental, and they are always personal. We can create something better.
Life sciences Home
Biotechnology Industry Position survey Australia's biotechnology industry drives economic growth
The 2019 Biotechnology Industry Position survey conducted by Ausbiotech and supported by Grant Thornton has revealed that new technologies across regenerative medicine and medicinal cannabis are disrupting the industry, and Australia's global strength in clinical trials continues to drive contributions to the economic and social fabric of the country.
Manufacturing Home
mid-sized business report Manufacturing is critical to our economy – how can we support the sector?
Although the knock-on effects of the Australian automotive industry exiting our country are yet to be fully understood, the industry is evolving, and manufacturing continues to be a major employer and critical to our overall economy.
Not for Profit Home
NATIONAL OUTCOMES MEASUREMENT PROGRAM A practical framework
Royal Commissions and federal budgets are critical things for Nonprofit human service providers to be thinking about at this point in time.
Real estate & construction Home
mid-sized business report Supporting affordable housing requires planning, certainty – and tax reform
There is a lot of noise around the property sector at the moment – and it’s not all positive. Prices are down – but this shouldn’t be a surprise when some markets (namely Sydney & Melbourne) saw unprecedented hikes in recent years.
Retail & consumer products Home
GNC Group Consulting The Technology Trap: Online innovation in retail
I recently attended the NRF Retail Big Show in New York, an overwhelming smorgasbord of retail technology and new store concepts.
Technology & media Home
  • Telecommunications
Scaling-up for Growth From start-up to scale-up
Navigating the complexities of growth and maintaining previous success is a challenge for all mid-size businesses.
  • Working at Grant Thornton
  • Student opportunities
  • Experienced careers
  • Contact us
Working at Grant Thornton Home
  • Flexibility
  • Your career and development
  • Diversity and inclusion
  • In the community
  • What we offer you
Student opportunities Home
  • Graduates
  • Vacationer Program
  • The application process
  • FAQs
  • Student application tips and tricks
Experienced careers Home
  • Client spotlight
  • Grant Thornton Australia | Audit, Tax and Advisory
  • Client alerts
  • 2015
  • Encouraging innovation in Australia’s Life Sciences and Biotechnology industries

Encouraging innovation in Australia’s Life Sciences and Biotechnology industries

29 Apr 2015
  • 2015
  • Transitioning support for auto supply chain companies
  • Innovation in Australia
  • New FBT entertainment cap introduced
  • New reporting obligations for multinational companies
  • Unlocking super
  • The truth behind business failure
  • 2015 Distinguished Family Business of the Year
  • Melbourne plan refresh: The 2050 metropolitan planning strategy
  • Tax alert: GST & remote housing accommodation
  • The Federal Government's Tax discussion paper released today
  • New fees hurt developers’ bottom line
  • Payroll Tax Rebate – Action before 23 November 2015
  • New South Wales State Budget 2015-16
  • Western Australian Real estate & construction update
  • Victoria Real estate & construction update
  • South Australia Real estate & construction update
  • Queensland Real estate & construction update
  • New South Wales Real estate & construction update
  • State revenue offices and the ATO information sharing
  • Redundant corporate entities?
  • Streamlined process for new business applications
  • Imported building materials under scrutiny
  • Tightened lending rules threaten industry growth
  • Any GST hike must be offset
  • New PM appoints Minister for Cities
  • Reforming Australia’s Federation and Tax System
  • A message from our Global Head of Real Estate & Construction
  • Adelaide CBD property outlook – Key considerations
  • The deadline is looming for the Exploration Development Incentive
  • Valuing Employee Share Schemes (ESS) – Impending Tax Changes
  • Queensland State Budget 2015-16
  • New restrictions on entertainment salary packaging
  • NADA conference day three
  • NADA conference day two
  • Do you have the keys to NADA 2015? Day 1
  • South Australian State Budget 2015-16
  • 27 Pay Periods in 2015/16
  • Corporate simplification and solvent liquidations
  • Fringe Benefits – Hidden FBT and deemed dividend issues
  • NSW Payroll Tax Rebate
  • SuperStream compliance
  • Should I maintain my SMSF?
  • Art and collectables as alternative investments
  • Tax alert: GST ruling published
  • Western Australian State Budget 2015-16
  • New funding opportunities for Australian food & beverage companies
  • Super fund investment choice – What are the options?
  • Nominating beneficiaries for your superannuation benefits
  • Superannuation consolidation
  • Victorian State Budget 2015/16
  • Encouraging innovation in Australia’s Life Sciences and Biotechnology industries
  • Fraud in focus: Fraud and corruption in Banking and Financial Services
  • Tax alert: Refunds of excess GST
  • New Employee Share Scheme Bill Introduced
  • SuperStream employer webinars
  • Staying vigilant against fraud
  • Tax Alert: Are you meeting your employment tax obligations?
  • Tax alert: No change to R&D tax offset rates
  • Act now to be ready for FATCA
  • Tax alert: Changes to Employee Share Scheme Tax Laws

For those in the business of innovating, ensuring sufficient funding is available has always been a concern.

The Research & Development (R&D) Tax Incentive has been a long-established source of funding and support for businesses in the research, development and early developmental commercialisation phases. The policy driver behind the R&D Tax Incentive is to encourage more companies to engage in R&D in Australia. And it’s working: a number of companies have publically stated that they have set up in Australia because of the support provided by the R&D Tax Incentive.

The R&D Tax Incentive has two tiers:

  • A 45% tax offset for businesses with an aggregate turnover of less than $20 million, which may be available as a cash rebate if the business is in losses (benefit of 15c in the dollar)
  • A 40% non-refundable tax offset for businesses with a turnover greater than $20 million (benefit of 10c in the dollar)

Even though the understanding of taxation support for R&D is very high within the Life Sciences and Biotechnology sphere in Australia, significant opportunities and complexities still exist. Therefore companies can make major gains by taking advantage of this support and streamlining the process they do this through.  

Tax opportunities for research, development and early phase commercialisation

Be certain whether your activities and/or expenditure are eligible for the R&D Tax Incentive
There are specific mechanisms under the R&D Tax Incentive to provide a company with certainty on the eligibility of its activities for the R&D Tax Incentive. An Advance Finding can provide this certainty, provided the company makes the application before the end of the financial year.  If the year-end has passed, companies may also request AusIndustry to undertake a review of the R&D claim made.  ATO private rulings are also available if a high level of certainty is required over the eligibility of expenditure incurred on R&D activities.

Claim for R&D activities you need to undertake offshore
Expenditure incurred outside of Australia is only eligible if an Advance Finding, lodged before the end of the financial year in which the activity is undertaken, is obtained.   Advance Findings do take time and require a rigorous understanding of the R&D Tax Incentive process and the provisions involved. Companies routinely get caught out by leaving the application too late and underestimating the procedural requirements involved. 

Foreign owned R&D
As noted above the policy driver for R&D is to encourage R&D to be undertaken in Australia.  It is recognised that sometimes Australian companies undertake (and indeed are compensated for) R&D on behalf of a foreign related company. Depending on the country in which the foreign company is located, and the agreements in place between the entities, it is possible to claim the R&D being done in Australia at the tax offset rates already mentioned.

Get the supporting documentation and cost identification processes right
Making sure the supporting documentation for R&D Tax Incentive claims are maintained and systems for identifying eligible R&D expenditure are as efficient as possible saves time and protects the eligibility of any R&D Tax Incentive claim.  Many companies unnecessarily take on too much of this burden, putting undue pressure on key research staff and risking the eligibility of the claim. Good support and advice is affordable and a great investment to streamline the process.

IP Management/Research location management

Unfortunately, Australia continues to lag global progress in supporting companies to locate their IP in Australia. ‘Patent-box’ provisions are increasingly being used around the world to ensure that companies that develop great new technology locally keep it onshore by providing tax breaks on revenue generated from such IP. Not only does this contribute to manufacturing being undertaken locally but it also ensures companies are not put in a ‘second-best’ position compared to companies locating their IP in tax preferential jurisdictions. There has certainly been a push the biotech community for such provisions be developed for Australia, however this has yet to gain traction with the Government.

In addition, some global jurisdictions offer excellent support for developers and early phase developmental manufacturing, and so Life Science and Biotechnology companies in the R&D phase should be giving serious thought to where and how they how they want to commercialise their product globally:  which global markets will they be going into and where will they want to undertake their manufacturing and full-scale production development? All of these considerations will impact where the ultimate technology and IP will be located.

Cross-border transactions, related party dealings and transfer pricing

As part of the recent modernisation of Australia’s transfer pricing rules, new provisions were introduced replacing the old transfer pricing regime. The new provisions contain special rules placing greater emphasis on record keeping and documentation, and create a significant administration burden on companies. Recognising this, the ATO has provided for a range of procedural safe-harbours that reduce the documentation burden in specific cases. However, Life Science and Biotechnology companies which commonly hold IP are broadly excluded from the safe-harbour provisions where there have related party dealings.   

Specifically, the safe-harbour for businesses with a turnover less than $25 million will not be available where a company has related-party dealings involving royalties, licence fees or research and development arrangements.

This means that Life Science and Biotechnology companies looking to global markets are very likely to be fully exposed to the full documentation requirements of the new transfer pricing provisions, making early planning critical to manage global manufacture, distribution and ongoing development, research and commercialisation. 

Where to from here for the R&D tax incentive?

The ATO and AusIndustry have signalled that they are looking more closely into arrangements related to R&D and the types of claims being made. Of particular interest to the ATO is the application of the “aggregate turnover” rules in light of company ownership structures. Companies should be aware of the grouping rules which apply to this test.

The most recent legislative change for R&D has been the introduction of a cap on the expenditure which can be subject to the tax offset each financial year. The cap is $100 million, and any amounts above this receive the R&D tax offset at the corporate tax rate. It is expected that this will impact directly only a very, very small number of companies. However, what is sometimes forgotten is the effect that this may have on companies that provide R&D services to these large R&D companies.

Companies have been public about coming to Australia because of the R&D tax incentive. If companies are unable to access the R&D tax incentive, they will likely look overseas for their projects particularly without further incentives to locate their IP in Australia. This will continue to have a limiting effect on the “spillover benefits” of the R&D Tax Incentive; the increased expertise and knowledge base in Australia, to the benefit of other local innovators.

Although the rate of offset has not been cut, it appears that this is still not off the table, with the Government still seeking to balance a budget and cut costs.  We wait to see what the May Budget for the 2016 year brings. 

For more information please contact

Sukvinder Heyer
Sukvinder Heyer
Partner Melbourne
Email address Sukvinder Heyer VCard
View full profile
Share this page
  • Share this page on Facebook LinkedIn
  • Share this page on Twitter Twitter
  • Share this page on LinkedIn LinkedIn
  • Share this page on Wechat WeChat
  • Share this page via email Email
  • Follow us on youtube
  • Follow us on linkedin
  • Follow us on twitter
  • Follow us on facebook
Connectclose
  • Contact us
  • Locations
  • Meet our people
  • Subscribe
  • Staff portal
Aboutclose
  • About us
  • Careers
  • News centre
  • Client alerts
  • Grant Thornton Foundation
  • Grant Thornton Affinity
Legalclose
  • Privacy
  • Compliance and ethics
  • Disclaimer
  • Site map

© 2021 Grant Thornton Australia Limited – All rights reserved

    • EN
    • Contact us